Rochester, Minn.-based Mayo Clinic has broken ground on a $9 million cancer center expansion at its New Prague, Minn., medical campus.
The Latest
Along with the premarket approval of Siemens' 3D breast-imaging technology, the FDA approved seven oncology and hematology drugs in September.
Six U.S. health systems and cancer centers have joined the recently launched Together for Supportive Cancer Care consortium alongside more than 30 research institutions and advocacy groups with the aim to make supportive cancer care the standard of care.
Michel Sadelain, MD, PhD, a CAR-T therapy innovator and one of the world's top immunologists, has left New York City-based Memorial Sloan Kettering Cancer Center for two new roles at Columbia University Irving Medical Center, also in New York City.
From 2012 to 2021, breast cancer incidence has risen 1%, with steep increases among young women and Asian American/Pacific Islander women, according to the American Cancer Society.
Moffitt Cancer Center patients will soon have access to on-demand virtual care services.
An AI-empowered blood test was able to more reliably identify ovarian cancer by detecting DNA fragments and protein biomarkers, according to a study published Sept. 30 in the American Association for Cancer Research's journal, Cancer Discovery.
The FDA's Oncologic Drugs Advisory Committee has voted to restrict the use of nivolumab and pembrolizumab immunotherapy drugs based on the programmed death-ligand 1 expression levels of patients, according to a Sept. 30 Medscape report.
Increased demand for colonoscopies has prompted healthcare leaders to hone preventive screening, service delivery and innovation strategies in recent years.1
Boston-based Dana-Farber Cancer Institute will lead 12 other health systems and academic institutions across the U.S. in a new cancer consortium aimed at addressing health equity and survival rates among pediatric populations.